New members joined the RDAF in May 2018

    4 Jun, 2018

    In May 2018, Swedish Orphan Biovitrum, a company specialized in the area of rare diseases, the Swiss umbrella patient organization ProRaris and the Swiss Foundation for Research on Muscle Diseases (SSEM/FSRMM) became members of the Rare Disease Action Forum (RDAF). In total, the Forum now hosts fifteen members who represent major groups of stakeholders in the area of rare diseases including industry, patient organizations, healthcare organizations, physicians and foundations for research. With its increased membership, the RDAF reinforces its contribution towards the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...